What is the current market valuation of the India transthyretin amyloidosis market?

The market valuation was $298.98 Million in 2024. Read More

What is the projected market size for the India transthyretin amyloidosis market by 2035?

The projected market size is $608.95 Million by 2035. Read More

What is the expected CAGR for the India transthyretin amyloidosis market during the forecast period 2025 - 2035?

The expected CAGR is 6.68% during the forecast period 2025 - 2035. Read More

Which companies are the key players in the India transthyretin amyloidosis market?

Key players include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Ionis Pharmaceuticals, Eisai Co., Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Horizon Therapeutics. Read More

What are the major drug segments in the India transthyretin amyloidosis market?

Major drug segments include Inotersen, Partisiran, Tafamidis, and others, with Tafamidis valued between $120.0 Million and $250.0 Million. Read More

How does the market perform in terms of indication segments?

The market for Wild type ATTR Amyloidosis is valued between $150.0 Million and $300.0 Million, while Hereditary ATTR Amyloidosis ranges from $148.98 Million to $308.95 Million. Read More

What distribution channels are utilized in the India transthyretin amyloidosis market?

Distribution channels include retail pharmacy, hospital pharmacy, and online pharmacy, with hospital pharmacy valued between $119.49 Million and $245.34 Million. Read More

What treatment segments are available in the India transthyretin amyloidosis market?

Treatment segments include small molecule treatment, Tafamidis, Diflunisal, RNAi Therapy, and Organ Transplantation, with Tafamidis valued between $120.0 Million and $250.0 Million. Read More

What is the significance of Tafamidis in the market?

Tafamidis appears to be a leading treatment option, with a valuation range of $120.0 Million to $250.0 Million. Read More

How does the market outlook appear for the future?

The market outlook appears positive, with a projected growth to $608.95 Million by 2035. Read More

India Transthyretin Amyloidosis Market

India Transthyretin Amyloidosis Market Research Report By Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), By Gender (Male, Female), By Treatment (Small Molecule Treatment) and By End-User (Ambulatory Surgical Center, Clinics) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.68%

2024 Market Size

$ 298.98 Million

2035 Market Size

$ 608.95 Million

Healthcare ● Updated April 2026 Report ID: MRFR/HC/54253-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Drug (USD Million)
  1. 4.1.1 Inotersen
  2. 4.1.2 Partisiran
  3. 4.1.3 Tafamidis
  4. 4.1.4 Others
2. 4.2 Food, Beverages & Nutrition, BY Indication (USD Million)
  1. 4.2.1 Wild type ATTR Amyloidosis
  2. 4.2.2 Hereditary ATTR Amyloidosis
3. 4.3 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  1. 4.3.1 Retail pharmacy
  2. 4.3.2 Hospital pharmacy
  3. 4.3.3 Online pharmacy
4. 4.4 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.4.1 Small molecule treatment
  2. 4.4.2 Tafamidis
  3. 4.4.3 Diflunisal
  4. 4.4.4 RNAi Therapy
  5. 4.4.5 Organ Transplantation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Alnylam Pharmaceuticals (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ionis Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eisai Co., Ltd. (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries Ltd. (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Horizon Therapeutics (IE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY DRUG
3. 6.3 INDIA MARKET ANALYSIS BY INDICATION
4. 6.4 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 INDIA MARKET ANALYSIS BY TREATMENT
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY TREATMENT, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Transthyretin Amyloidosis Market Segmentation

India Transthyretin Amyloidosis Market By Drug (USD Million, 2025-2035)

Inotersen
Partisiran
Tafamidis
Others

India Transthyretin Amyloidosis Market By Indication (USD Million, 2025-2035)

Wild type ATTR Amyloidosis
Hereditary ATTR Amyloidosis

India Transthyretin Amyloidosis Market By Distribution Channel (USD Million, 2025-2035)

Retail pharmacy
Hospital pharmacy
Online pharmacy

India Transthyretin Amyloidosis Market By Treatment (USD Million, 2025-2035)

Small molecule treatment
Tafamidis
Diflunisal
RNAi Therapy
Organ Transplantation

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”